ErbB receptors in the biology and pathology of the aerodigestive tract

Experimental Cell Research

Volumn 315, Issue 4, 2009, Pages 572-582

  Morgan, Sarah ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aerodigestive cancer; EGFR; ErbB signaling; ErbB1; ErbB2; ErbB3; ErbB4; Esophageal cancer; Head and neck cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE; STAT PROTEIN;

CLASSIFICATION; DRUG DELIVERY SYSTEM; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; HUMAN; LUNG TUMOR; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

DRUG DELIVERY SYSTEMS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS V-ERBB; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT TRANSCRIPTION FACTORS;

EID: 62649157431     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.08.009     Document Type: Review

References (140)

1. A. Argiris, C. Eng, Epidemiology, staging, and screening of head and neck cancer, Cancer Treat. Res. 114 (2003) 15-60.
2. C.Y. Fan, Genetic alterations in head and neck cancer: interactions among environmental carcinogens, cell cycle control, and host DNA repair, Curr. Oncol. Rep. 3 (2001) 66-71.
3. G. D'Souza, A.R. Kreimer, R. Viscidi, M. Pawlita, C. Fakhry, W.M. Koch, W.H. Westra, M.L. Gillison, Case-control study of human papillomavirus and oropharyngeal cancer, N. Engl. J. Med. 356 (2007) 1944-1956.
4. J. Califano, P.L. Leong, W.M. Koch, C.F. Eisenberger, D. Sidransky, W.H. Westra, Second esophageal tumors in patients with head and neck squamous cell carcinoma: an assessment of clonal relationships, Clin. Cancer Res. 5 (1999) 1862-1867.
5. J.T. Licciardello, M.R. Spitz, W.K. Hong, Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung, Int. J. Radiat. Oncol. Biol. Phys. 17 (1989) 467-476.
6. L.H. Schwartz, M. Ozsahin, G.N. Zhang, E. Touboul, F. De Vataire, P. Andolenko, J. Lacau-Saint-Guily, A. Laugier, M. Schlienger, Synchronous and metachronous head and neck carcinomas, Cancer 74 (1994) 1933-1938.
7. X. Leon, M. Quer, S. Diez, C. Orus, A. Lopez-Pousa, J. Burgues, Second neoplasm in patients with head and neck cancer, Head Neck 21 (1999) 204-210.
8. K.F. Trivers, S.A. Sabatino, S.L. Stewart, Trends in esophageal cancer incidence by histology, United States, 1998-2003, Int. J. Cancer 123 (2008) 1422-1428.
9. R.S. Holmes, T.L. Vaughan, Epidemiology and pathogenesis of esophageal cancer, Semin. Radiat. Oncol. 17 (2007) 2-9.
10. A.M. Mandard, P. Hainaut, M. Hollstein, Genetic steps in the development of squamous cell carcinoma of the esophagus, Mutat. Res. 462 (2000) 335-342.
11. R. Kim, J.L. Weissfeld, J.C. Reynolds, L.H. Kuller, Etiology of Barrett's metaplasia and esophageal adenocarcinoma, Cancer Epidemiol. Biomarkers. Prev. 6 (1997) 369-377.
12. D.J. Drewitz, R.E. Sampliner, H.S. Garewal, The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years, Am. J. Gastroenterol. 92 (1997) 212-215.
13. D.C. Farrow, T.L. Vaughan, C. Sweeney, M.D. Gammon, W.H. Chow, H.A. Risch, J.L. Stanford, P.D. Hansten, S.T. Mayne, J.B. Schoenberg, H. Rotterdam, H. Ahsan, A.B. West, R. Dubrow, J.F. Fraumeni Jr., W.J. Blot, Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer, Cancer Causes Control 11 (2000) 231-238.
14. W. Ye, W.H. Chow, J. Lagergren, L. Yin, O. Nyren, Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery, Gastroenterology 121 (2001) 1286-1293.
15. W.H. Chow, W.J. Blot, T.L. Vaughan, H.A. Risch, M.D. Gammon, J.L. Stanford, R. Dubrow, J.B. Schoenberg, S.T. Mayne, D.C. Farrow, H. Ahsan, A.B. West, H. Rotterdam, S. Niwa, J.F. Fraumeni Jr., Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia, J. Natl. Cancer Inst. 90 (1998) 150-155.
16. J. Lagergren, R. Bergstrom, O. Nyren, Association between body mass and adenocarcinoma of the esophagus and gastric cardia, Ann. Intern. Med. 130 (1999) 883-890.
17. A.H. Wu, P. Wan, L. Bernstein, A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States), Cancer Causes Control 12 (2001) 721-732.
18. J. Lagergren, Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?, Gut 54 (Suppl 1) (2005) i1-i5.
19. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, R.B. Cohen, C.U. Jones, R. Sur, D. Raben, J. Jassem, R. Ove, M.S. Kies, J. Baselga, H. Youssoufian, N. Amellal, E.K. Rowinsky, K.K. Ang, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N. Engl. J. Med. 354 (2006) 567-578.
20. Y. Kawaguchi, K. Kono, K. Mimura, H. Sugai, H. Akaike, H. Fujii, Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma, Int. J. Cancer 120 (2007) 781-787.
21. H. Safran, M. Suntharalingam, T. Dipetrillo, T. Ng, L.A. Doyle, M. Krasna, A. Plette, D. Evans, H.Wanebo, P. Akerman, J. Spector, N. Kennedy, T. Kennedy, Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity, Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 391-395.
22. N.E. Hynes, H.A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat. Rev. Cancer 5 (2005) 341-354.
23. M. Scaltriti, J. Baselga, The epidermal growth factor receptor pathway: a model for targeted therapy, Clin. Cancer Res. 12 (2006) 5268-5272.
24. T. Holbro, G. Civenni, N.E. Hynes, The ErbB receptors and their role in cancer progression, Exp. Cell Res. 284 (2003) 99-110.
25. R.J. Leeman, V.W. Lui, J.R. Grandis, STAT3 as a therapeutic target in head and neck cancer, Expert Opin. Biol. Ther. 6 (2006) 231-241.
26. M.V. Karamouzis, J.R. Grandis, A. Argiris, Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas, Jama 298 (2007) 70-82.
27. P. O-charoenrat, P. Rhys-Evans, S. Eccles, Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells, Int. J. Cancer 88 (2000) 759-765.
28. S. Kalyankrishna, J.R. Grandis, Epidermal growth factor receptor biology in head and neck cancer, J. Clin. Oncol. 24 (2006) 2666-2672.
29. C. Qiu, M.K. Tarrant, S.H. Choi, A. Sathyamurthy, R. Bose, S. Banjade, A. Pal, W.G. Bornmann, M.A. Lemmon, P.A. Cole, D.J. Leahy, Mechanism of activation and inhibition of the HER4/ErbB4 kinase, Structure 16 (2008) 460-467.
30. R.G. Pomerantz, J.R. Grandis, The role of epidermal growth factor receptor in head and neck squamous cell carcinoma, Curr. Oncol. Rep. 5 (2003) 140-146.
31. P.J. Miettinen, J.E. Berger, J. Meneses, Y. Phung, R.A. Pedersen, Z. Werb, R. Derynck, Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor, Nature 376 (1995) 337-341.
32. K.F. Lee, H. Simon, H. Chen, B. Bates, M.C. Hung, C. Hauser, Requirement for neuregulin receptor erbB2 in neural and cardiac development, Nature 378 (1995) 394-398.
33. M. Gassmann, F. Casagranda, D. Orioli, H. Simon, C. Lai, R. Klein, G. Lemke, Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor, Nature 378 (1995) 390-394.
34. D. Riethmacher, E. Sonnenberg-Riethmacher, V. Brinkmann, T. Yamaai, G.R. Lewin, C. Birchmeier, Severe neuropathies in mice with targeted mutations in the ErbB3 receptor, Nature 389 (1997) 725-730.
35. T. Ekberg, M. Nestor, M. Engstrom, H. Nordgren, K. Wester, J. Carlsson, M. Anniko, Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue, Int. J. Oncol. 26 (2005) 1177-1185.
36. K. Erjala, M. Sundvall, T.T. Junttila, N. Zhang, M. Savisalo, P. Mali, J. Kulmala, J. Pulkkinen, R. Grenman, K. Elenius, Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells, Clin. Cancer Res. 12 (2006) 4103-4111.
37. R. Bei, A. Budillon, L. Masuelli, V. Cereda, D. Vitolo, E. Di Gennaro, V. Ripavecchia, C. Palumbo, F. Ionna, S. Losito, A. Modesti, M.H. Kraus, R. Muraro, Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients, J. Pathol. 204 (2004) 317-325.
38. J.C. de Vicente, I. Esteban, P. Germana, A. Germana, J.A. Vega, Expression of ErbB-3 and ErbB-4 protooncogene proteins in oral squamous cell carcinoma: a pilot study, Med. Oral 8 (2003) 374-381.
39. P. O-charoenrat, P. Rhys-Evans, S. Eccles, Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression, Anticancer Res. 21 (2001) 1953-1963.
40. R. Bei, G. Pompa, D. Vitolo, E. Moriconi, L. Ciocci, M. Quaranta, L. Frati, M.H. Kraus, R. Muraro, Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma, J. Pathol. 195 (2001) 343-348.
41. J. Rubin Grandis, M.F. Melhem, W.E. Gooding, R. Day, V.A. Holst, M.M. Wagener, S.D. Drenning, D.J. Tweardy, Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival, J. Natl. Cancer Inst. 90 (1998) 824-832.
42. J. Rubin Grandis, D.J. Tweardy, M.F. Melhem, Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma, Clin. Cancer Res. 4 (1998) 13-20.
43. J.R. Grandis, D.J. Tweardy, Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer, Cancer Res. 53 (1993) 3579-3584.
44. R.P. Takes, R.J. Baatenburg de Jong, E. Schuuring, S.V. Litvinov, J. Hermans, J.H. Van Krieken, Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell, Anticancer Res. 18 (1998) 4793-4800.
45. S. Kim, J.R. Grandis, A. Rinaldo, R.P. Takes, A. Ferlito, Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer, Head Neck 30 (2008) 667-674.
46. M. Hanawa, S. Suzuki, Y. Dobashi, T. Yamane, K. Kono, N. Enomoto, A. Ooi, EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus, Int. J. Cancer 118 (2006) 1173-1180.
47. L. Gibault, J.P. Metges, V. Conan-Charlet, P. Lozac'h, M. Robaszkiewicz, C. Bessaguet, N. Lagarde, A. Volant, Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer, Br. J. Cancer 93 (2005) 107-115.
48. D.R. Ferry, M. Anderson, K. Beddard, S. Tomlinson, P. Atherfold, J. Obszynska, R. Harrison, J. Jankowski, A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response, Clin. Cancer Res. 13 (2007) 5869-5875.
49. J.A. Jankowski, N.A. Wright, S.J. Meltzer, G. Triadafilopoulos, K. Geboes, A.G. Casson, D. Kerr, L.S. Young, Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus, Am. J. Pathol. 154 (1999) 965-973.
50. I. Uberall, Z. Kolar, R. Trojanec, J. Berkovcova, M. Hajduch, The status and role of ErbB receptors in human cancer, Exp. Mol. Pathol. 84 (2008) 79-89.
51. K.L.Wang, T.T.Wu, I.S. Choi, H.Wang, E. Reseetkova, A.M. Correa, W.L. Hofstetter, S.G. Swisher, J.A. Ajani, A. Rashid, C.T. Albarracin, Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome, Cancer 109 (2007) 658-667.
52. S. Ozawa, M. Ueda, N. Ando, N. Shimizu, O. Abe, Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas, Cancer 63 (1989) 2169-2173.
53. J.R. Grandis, D.J. Tweardy, M.F. Melhem, Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma, Clin. Cancer Res. 4 (1998) 13-20.
54. J. Rubin Grandis, Q. Zeng, D.J. Tweardy, Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines, Nat. Med. 2 (1996) 237-240.
55. J. Rubin Grandis, M.F. Melhem, E.L. Barnes, D.J. Tweardy, Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck, Cancer 78 (1996) 1284-1292.
56. H. Nagatsuka, Y. Ishiwari, H. Tsujigiwa, K. Nakano, N. Nagai, Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions, Oral. Oncol. 37 (2001) 599-604.
57. J.E.A. Rubin Grandis, Q. Zeng, S.D. Drenning, D.J. Tweardy, Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line, Int. J. Oncol. 13 (1998) 375-378.
58. M.L. Amador, D. Oppenheimer, S. Perea, A. Maitra, G. Cusatis, C. Iacobuzio-Donahue, S.D. Baker, R. Ashfaq, C. Takimoto, A. Forastiere, M. Hidalgo, An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors, Cancer Res. 64 (2004) 9139-9143.
59. J.R. Grandis, Q. Zeng, D.J. Tweardy, Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines, Nat. Med. 2 (1996) 237-240.
60. A.C. Ford, J.R. Grandis, Targeting epidermal growth factor receptor in head and neck cancer, Head Neck 25 (2003) 67-73.
61. V.H. Schartinger, L. Kacani, J. Andrle, I. Schwentner, M. Wurm, P. Obrist,W. Oberaigner, G.M. Sprinzl, Pharmacodiagnostic value of the HER family in head and neck squamous cell carcinoma, ORL J. Otorhinolaryngol. Relat. Spec. 66 (2004) 21-26.
62. N. Normanno, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, A. De Luca, F. Caponigro, D.S. Salomon, The ErbB receptors and their ligands in cancer: an overview, Curr. Drug. Targets. 6 (2005) 243-257.
63. A.M. Egloff, J. Grandis, Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma, Expert Opin. Ther. Targets. 10 (2006) 639-647.
64. A. Cavalot, T. Martone, N. Roggero, G. Brondino, M. Pagano, G. Cortesina, Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas, Head Neck 29 (2007) 655-664.
65. R.H. Hardwick, C.P. Barham, P. Ozua, P.V. Newcomb, P. Savage, R. Powell, J. Rahamin, D. Alderson, Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis, Eur. J. Surg. Oncol. 23 (1997) 30-35.
66. H. Friess, A. Fukuda, W.H. Tang, A. Eichenberger, N. Furlan, A. Zimmermann, M. Korc, M.W. Buchler, Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3,World J. Surg. 23 (1999) 1010-1018.
67. L.S. Wang, K.C. Chow, K.H. Chi, C.C. Liu, W.Y. Li, J.H. Chiu, M.H. Huang, Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors, Am. J. Gastroenterol. 94 (1999) 1933-1940.
68. M. Akamatsu, T. Matsumoto, K. Oka, S. Yamasaki, H. Sonoue, Y. Kajiyama, M. Tsurumaru, K. Sasai, c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma, Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 1323-1327.
69. K. Mimura, K. Kono, M. Hanawa, F. Mitsui, H. Sugai, N. Miyagawa, A. Ooi, H. Fujii, Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma, Br. J. Cancer 92 (2005) 1253-1260.
70. E. Rossi, V. Villanacci, G. Bassotti, D.D. Casa, G. Missale, L. Minelli, R. Cestari, Her-2/neu in Barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization, Diagn. Mol. Pathol. 15 (2006) 125-130.
71. L.B. Koppert, B.P. Wijnhoven, H. van Dekken, H.W. Tilanus, W.N. Dinjens, The molecular biology of esophageal adenocarcinoma, J. Surg. Oncol. 92 (2005) 169-190.
72. U. Reichelt, P. Duesedau, M. Tsourlakis, A. Quaas, B.C. Link, P.G. Schurr, J.T. Kaifi, S.J. Gros, E.F. Yekebas, A. Marx, R. Simon, J.R. Izbicki, G. Sauter, Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus, Mod. Pathol. 20 (2007) 120-129.
73. M.A. Guervos, C.A. Marcos, M. Hermsen, A.S. Nuno, C. Suarez, J.L. Llorente, Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas, Cell Oncol. 29 (2007) 327-334.
74. Y. Hasegawa, M. Goto, N. Hanai, K. Ijichi, A. Terada, I. Hyodo, T. Ogawa, M. Fukushima, Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma, Oncology 73 (2007) 104-111.
75. F. Montemurro, G. Valabrega, M. Aglietta, Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity, Expert Opin. Biol. Ther. 7 (2007) 257-268.
76. N. Kondo, Y. Ishiguro, M. Kimura, D. Sano, K. Fujita, A. Sakakibara, T. Taguchi, G. Toth, H. Matsuda, M. Tsukuda, Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab, Oncol. Rep. 20 (2008) 373-378.
77. K. Shirai, P.E. O'Brien, Molecular targets in squamous cell carcinoma of the head and neck, Curr. Treat Options Oncol. 8 (2007) 239-251.
78. P. Sunpaweravong, S. Sunpaweravong, P. Puttawibul, W. Mitarnun, C. Zeng, A.E. Baron, W. Franklin, S. Said, M. Varella-Garcia, Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma, J. Cancer Res. Clin. Oncol. 131 (2005) 111-119.
79. M. Dreilich, A.Wanders, D. Brattstrom, S. Bergstrom, P. Hesselius, G. Wagenius, M. Bergqvist, HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival, Dis. Esophagus 19 (2006) 224-231.
80. J.S. Ross, B.J. McKenna, The HER-2/biNneub/iNOncogene in Tumors of the Gastrointestinal Tract, Cancer Investig. 19 (2001) 554-568.
81. R. Langer, B.H. Von Rahden, J. Nahrig, C. Von Weyhern, R. Reiter, M. Feith, H.J. Stein, J.R. Siewert, H. Hofler, M. Sarbia, Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study, J. Clin. Pathol. 59 (2006) 631-634.
82. P. O-charoenrat, P.H. Rhys-Evans, H. Modjtahedi, S.A. Eccles, The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma, Oral. Oncol. 38 (2002) 627-640.
83. S.J. Rogers, K.J. Harrington, P. Rhys-Evans, O.C.P., S.A. Eccles, Biological significance of c-erbB family oncogenes in head and neck cancer, Cancer Metastasis Rev. 24 (2005) 47-69.
84. S. Shintani, T. Funayama, Y. Yoshihama, R.E. Alcalde, T. Matsumura, Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma, Cancer Lett. 95 (1995) 79-83.
85. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, J. Christensen, T. Kosaka, A.J. Holmes, A.M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B.E. Johnson, L.C. Cantley, P.A. Janne, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science 316 (2007) 1039-1043.
86. D. Peng, E.A. Sheta, S.M. Powell, C.A. Moskaluk, K. Washington, I.L. Goldknopf, W. El-Rifai, Alterations in Barrett's-related adenocarcinomas: a proteomic approach, Int. J. Cancer 122 (2008) 1303-1310.
87. P. O-charoenrat, P.H. Rhys-Evans, D.J. Archer, S.A. Eccles, C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlationwithmatrixmetalloproteinases and vascular endothelial growth factors, Oral. Oncol. 38 (2002) 73-80.
88. W. Xia, Y.K. Lau, H.Z. Zhang, F.Y. Xiao, D.A. Johnston, A.R. Liu, L. Li, R.L. Katz, M.C. Hung, Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members, Clin. Cancer Res. 5 (1999) 4164-4174.
89. S. Xu, J. Kitayama, H. Yamashita, D. Souma, H. Nagawa, Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma, J. Surg. Oncol. 97 (2008) 44-50.
90. C.Y. Ni, M.P. Murphy, T.E. Golde, G. Carpenter, gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase, Science 294 (2001) 2179-2181.
91. G. Carpenter, ErbB-4: mechanism of action and biology, Exp. Cell Res. 284 (2003) 66-77.
92. G. Carpenter, Nuclear localization and possible functions of receptor tyrosine kinases, Curr. Opin. Cell Biol. 15 (2003) 143-148.
93. S. Temam, H. Kawaguchi, A.K. El-Naggar, J. Jelinek, H. Tang, D.D. Liu, W. Lang, J.P. Issa, J.J. Lee, L. Mao, Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer, J. Clin. Oncol. 25 (2007) 2164-2170.
94. E.L. Kwak, J. Jankowski, S.P. Thayer, G.Y. Lauwers, B.W. Brannigan, P.L. Harris, R.A. Okimoto, S.M. Haserlat, D.R. Driscoll, D. Ferry, B. Muir, J. Settleman, C.S. Fuchs, M.H. Kulke, D.P. Ryan, J.W. Clark, D.C. Sgroi, D.A. Haber, D.W. Bell, Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas, Clin. Cancer Res. 12 (2006) 4283-4287.
95. F.A. Puhringer-Oppermann, H.J. Stein, M. Sarbia, Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas, Dis. Esophagus 20 (2007) 9-11.
96. T. Sudo, K. Mimori, H. Nagahara, T. Utsunomiya, H. Fujita, Y. Tanaka, K. Shirouzu, H. Inoue, M. Mori, Identification of EGFR mutations in esophageal cancer, Eur. J. Surg. Oncol. 33 (2007) 44-48.
97. J.C. Sok, F.M. Coppelli, S.M. Thomas, M.N. Lango, S. Xi, J.L. Hunt, M.L. Freilino, M.W. Graner, C.J. Wikstrand, D.D. Bigner, W.E. Gooding, F.B. Furnari, J.R. Grandis, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting, Clin. Cancer Res. 12 (2006) 5064-5073.
98. N. Sugawa, A.J. Ekstrand, C.D. James, V.P. Collins, Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 8602-8606.
99. A.J. Ekstrand, C.D. James,W.K. Cavenee, B. Seliger, R.F. Pettersson, V.P. Collins, Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo, Cancer Res. 51 (1991) 2164-2172.
100. J.R. Grandis, J.C. Sok, Signaling through the epidermal growth factor receptor during the development of malignancy, Pharmacol. Ther. 102 (2004) 37-46.
101. M.D. Marmor, K.B. Skaria, Y. Yarden, Signal transduction and oncogenesis by ErbB/HER receptors, Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 903-913.
102. A.P. Sutter,M. Zeitz, H. Scherubl, Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer, Onkologie 27 (2004) 17-21.
103. C.D. Andl, T. Mizushima, K. Oyama, M. Bowser, H. Nakagawa, A.K. Rustgi, EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes, Am. J. Physiol. Gastrointest. Liver Physiol. 287 (2004) G1227-1237.
104. K. Oyama, T. Okawa, H. Nakagawa, M. Takaoka, C.D. Andl, S.H. Kim, A. Klein-Szanto, J.A. Diehl, M. Herlyn, W. El-Deiry, A.K. Rustgi, AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture, Oncogene 26 (2007) 2353-2364.
105. N. Taira, H. Doihara, T. Oota, F. Hara, T. Shien, H. Takahashi, S. Yoshitomi, Y. Ishibe, N. Shimizu, Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro, Acta. Med. Okayama 60 (2006) 25-34.
106. T. Akimoto, T. Nonaka, K. Harashima, H. Ishikawa, H. Sakurai, N. Mitsuhashi, Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro, Anticancer Res. 24 (2004) 811-819.
107. J. Okano, I. Gaslightwala, M.J. Birnbaum, A.K. Rustgi, H. Nakagawa, Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation, J. Biol. Chem. 275 (2000) 30934-30942.
108. W.S. Hlavacek, J.R. Faeder, M.L. Blinov, R.G. Posner, M. Hucka, W. Fontana, Rules for modeling signal-transduction systems, Sci. STKE 2006 (2006) re6.
109. J. Albanell, J. Codony-Servat, F. Rojo, J.M. Del Campo, S. Sauleda, J. Anido, G. Raspall, J. Giralt, J. Rosello, R.I. Nicholson, J. Mendelsohn, J. Baselga, Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/ transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments, Cancer Res. 61 (2001) 6500-6510.
110. X. Shen, R.H. Kramer, Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor, Am. J. Pathol. 165 (2004) 1315-1329.
111. E. Ako, Y. Yamashita, M. Ohira, M. Yamazaki, T. Hori, N. Kubo, T. Sawada, K. Hirakawa, The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo, Oncol. Rep. 17 (2007) 887-893.
112. E.B. Haura, J. Turkson, R. Jove, Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer, Nat. Clin. Pract. Oncol. 2 (2005) 315-324.
113. T. Bowman, R. Garcia, J. Turkson, R. Jove, STATs in oncogenesis, Oncogene 19 (2000) 2474-2488.
114. K.M. Quesnelle, A.L. Boehm, J.R. Grandis, STAT-mediated EGFR signaling in cancer, J. Cell Biochem. 102 (2007) 311-319.
115. R.G. Pomerantz, J.R. Grandis, The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy, Semin. Oncol. 31 (2004) 734-743.
116. J.R. Grandis, S.D. Drenning, A. Chakraborty, M.Y. Zhou, Q. Zeng, A.S. Pitt, D.J. Tweardy, Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro, J. Clin. Invest. 102 (1998) 1385-1392.
117. J.R. Grandis, S.D. Drenning, Q. Zeng, S.C. Watkins, M.F. Melhem, S. Endo, D.E. Johnson, L. Huang, Y. He, J.D. Kim, Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo, Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4227-4232.
118. A. Boehm, M. Sen, R.R. Seethala, W.E. Gooding, M. Freilino, S.M. W.Wong, D.E. Johnson, J.R. Grandis, Combined targeting of EGFR, STAT3, and Bcl-XL enhances antitumor effects in squamous cell carcinoma of the head and neck, Molecular Pharmacology (In Press).
119. S. Xi, Q. Zhang, W.E. Gooding, T.E. Smithgall, J.R. Grandis, Constitutive activation of Stat5b contributes to carcinogenesis in vivo, Cancer Res. 63 (2003) 6763-6771.
120. D.S. Schrump, D.M. Nguyen, The epidermal growth factor receptor-STAT pathway in esophageal cancer, Cancer J. 7 (2001) 108-111.
121. S. Xi, Q. Zhang, K.F. Dyer, E.C. Lerner, T.E. Smithgall,W.E. Gooding, J. Kamens, J.R. Grandis, Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck, J. Biol. Chem. 278 (2003) 31574-31583.
122. A. Thelemann, F. Petti, G. Griffin, K. Iwata, T. Hunt, T. Settinari, D. Fenyo, N. Gibson, J.D. Haley, Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells, Mol. Cell Proteomics 4 (2005) 356-376.
123. D.C. Schonwasser, R.M. Marais, C.J. Marshall, P.J. Parker, Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes, Mol. Cell Biol. 18 (1998) 790-798.
124. A. Wells, J.R. Grandis, Phospholipase C-gamma1 in tumor progression, Clin. Exp. Metastasis 20 (2003) 285-290.
125. S.M. Thomas, F.M. Coppelli, A. Wells, W.E. Gooding, J. Song, J. Kassis, S.D. Drenning, J.R. Grandis, Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma, Cancer Res. 63 (2003) 5629-5635.
126. J. Wang, X. Zhang, S.M. Thomas, J.R. Grandis, A.Wells, Z.G. Chen, R.L. Ferris, Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR, Oncogene 24 (2005) 5897-5904.
127. A.J. Ridley, H.F. Paterson, C.L. Johnston, D. Diekmann, A. Hall, The small GTP-binding protein rac regulates growth factor-induced membrane ruffling, Cell 70 (1992) 401-410.
128. V. Kundra, J.A. Escobedo, A. Kazlauskas, H.K. Kim, S.G. Rhee, L.T. Williams, B.R. Zetter, Regulation of chemotaxis by the platelet-derived growth factor receptor-beta, Nature 367 (1994) 474-476.
129. S. Luangdilok, C. Box, L. Patterson, W. Court, K. Harrington, L. Pitkin, P. Rhys-Evans, O.C.P., S. Eccles, Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck, Cancer Res. 67 (2007) 7907-7916.
130. N.E. Bhola, J.R. Grandis, Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer, Front Biosci. 13 (2008) 1857-1865.
131. V.W. Lui, S.M. Thomas, Q. Zhang, A.L. Wentzel, J.M. Siegfried, J.Y. Li, J.R. Grandis, Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor, Oncogene 22 (2003) 6183-6193.
132. H. Niwa, A.L.Wentzel, M. Li,W.E. Gooding, V.W. Lui, J.R. Grandis, Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck, Clin. Cancer Res. 9 (2003) 5028-5035.
133. Q. Zhang, S.M. Thomas, S. Xi, A.L. Wentzel, T.E. Smithgall, J.M. Siegfried, W.E. Gooding, J.R. Grandis, Src family kinases mediate epidermal growth factor receptor (EGFR) ligand cleavage and EGFR activation by gastrin releasing peptide (GRP) in head and neck squamous cell carcinoma (HNSCC). Poster presented at American Association of Cancer Research 95th Annual Meeting, Orlando, FL., Proceedings of the American Association of Cancer Research, 45:194, 2004.
134. Q. Zhang, S.M. Thomas, V.W. Lui, S. Xi, J.M. Siegfried, H. Fan, T.E. Smithgall, G.B. Mills, J.R. Grandis, Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation, Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 6901-6906.
135. Q. Zhang, N.E. Bhola, V.W. Lui, D.R. Siwak, S.M. Thomas, C.T. Gubish, J.M. Siegfried, G.B. Mills, D. Shin, J.R. Grandis, Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer, Mol. Cancer Ther. 6 (2007) 1414-1424.
136. M.S. Chang, H.S. Lee, B.L. Lee, Y.T. Kim, J.S. Lee, W.H. Kim, Differential protein expression between esophageal squamous cell carcinoma and dysplasia, and prognostic significance of protein markers, Pathol. Res. Pract. 201 (2005) 417-425.
137. J.H. Fu, D.K. Yang, Y.C. Huang, G.Q. Hu, [Expressions of epithelial growth factor receptor and E-cadherin in esophageal carcinoma and their correlation], Ai. Zheng. 24 (2005) 241-245.
138. S.M. Lagarde, F.J. ten Kate, D.J. Richel, G.J. Offerhaus, J.J. van Lanschot, Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction, Ann. Surg. Oncol. 14 (2007) 977-991.
139. E.E. Vokes, E. Chu, Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers, Oncology (Willist. Park) 20 (2006) 15-25.
140. M.L. Janmaat, M.I. Gallegos-Ruiz, J.A. Rodriguez, G.A. Meijer, W.L. Vervenne, D.J. Richel, C. Van Groeningen, G. Giaccone, Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients, J. Clin. Oncol. 24 (2006) 1612-1619.